Cancer metastasis: Mechanisms of inhibition by melatonin
- PMID: 27706852
- DOI: 10.1111/jpi.12370
Cancer metastasis: Mechanisms of inhibition by melatonin
Abstract
Melatonin is a naturally occurring molecule secreted by the pineal gland and known as a gatekeeper of circadian clocks. Mounting evidence indicates that melatonin, employing multiple and interrelated mechanisms, exhibits a variety of oncostatic properties in a myriad of tumors during different stages of their progression. Tumor metastasis, which commonly occurs at the late stage, is responsible for the majority of cancer deaths; metastases lead to the development of secondary tumors distant from a primary site. In reference to melatonin, the vast majority of investigations have focused on tumor development and progression at the primary site. Recently, however, interest has shifted toward the role of melatonin on tumor metastases. In this review, we highlight current advances in understanding the molecular mechanisms by which melatonin counteracts tumor metastases, including experimental and clinical observations; emphasis is placed on the impact of both cancer and non-neoplastic cells within the tumor microenvironment. Due to the broad range of melatonin's actions, the mechanisms underlying its ability to interfere with metastases are numerous. These include modulation of cell-cell and cell-matrix interaction, extracellular matrix remodeling by matrix metalloproteinases, cytoskeleton reorganization, epithelial-mesenchymal transition, and angiogenesis. The evidence discussed herein will serve as a solid foundation for urging basic and clinical studies on the use of melatonin to understand and control metastatic diseases.
Keywords: angiogenesis; epithelial-mesenchymal transition; matrix metalloproteinase; melatonin; metastasis.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Melatonin as a potential inhibitory agent in head and neck cancer.Oncotarget. 2017 Aug 9;8(52):90545-90556. doi: 10.18632/oncotarget.20079. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163852 Free PMC article. Review.
-
New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence.Cancer Metastasis Rev. 2020 Mar;39(1):303-320. doi: 10.1007/s10555-020-09845-2. Cancer Metastasis Rev. 2020. PMID: 32086631 Review.
-
Basic mechanisms involved in the anti-cancer effects of melatonin.Curr Med Chem. 2010;17(36):4462-81. doi: 10.2174/092986710794183015. Curr Med Chem. 2010. PMID: 21062257 Review.
-
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.Int J Mol Sci. 2017 Apr 17;18(4):843. doi: 10.3390/ijms18040843. Int J Mol Sci. 2017. PMID: 28420185 Free PMC article. Review.
-
Melatonin and Cancer Hallmarks.Molecules. 2018 Feb 26;23(3):518. doi: 10.3390/molecules23030518. Molecules. 2018. PMID: 29495398 Free PMC article. Review.
Cited by
-
The emerging role of EGFL6 in angiogenesis and tumor progression.Int J Med Sci. 2020 May 25;17(10):1320-1326. doi: 10.7150/ijms.45129. eCollection 2020. Int J Med Sci. 2020. PMID: 32624687 Free PMC article. Review.
-
Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing.Oxid Med Cell Longev. 2020 May 21;2020:6841581. doi: 10.1155/2020/6841581. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32566095 Free PMC article. Review.
-
Dihydromyricetin Inhibited Migration and Invasion by Reducing S100A4 Expression through ERK1/2/β-Catenin Pathway in Human Cervical Cancer Cell Lines.Int J Mol Sci. 2022 Dec 1;23(23):15106. doi: 10.3390/ijms232315106. Int J Mol Sci. 2022. PMID: 36499426 Free PMC article.
-
Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer.Front Oncol. 2019 Jul 9;9:525. doi: 10.3389/fonc.2019.00525. eCollection 2019. Front Oncol. 2019. PMID: 31355130 Free PMC article.
-
Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.Cancer Sci. 2022 Jul;113(7):2232-2245. doi: 10.1111/cas.15338. Epub 2022 May 29. Cancer Sci. 2022. PMID: 35298069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources